Asarfi Hospital Limited · BSE:ASARFI
Asarfi Hospital — Q1 FY2025-26 Earnings Presentation
21 slides from Asarfi Hospital's earnings presentation, Aug 7, 2025
Slide 1: Cover letter to BSE for Investor Presentation Q1 FY25-26
असफ हॉ ीटल सबके िलए ा AHL/AO/2025/938 Date: 07.08.2025 To The BSE Limited The Listing Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001 Sub: Investor Presentation for Q1 FY25-26. Ref: Scrip Code: 543943 Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obli
Slide 2: Investor Presentation Q1'FY2025-26
Investor Presentation Q1’FY2025-26
Slide 3: Content
1 Company Overview 2 Leadership Team Content Key Highlights 3 4 Financial Performance 5 Operational Performance 2
Slide 4: Asarfi Hospital: At a Glance
Asarfi Hospital: At a Glance Established in 2005, Asarfi Hospital Limited (AHL) is serving the people of Dhanbad and its neighbouring areas for the last 20 years with affordable and best in class healthcare facilities. Operates two hospitals across Dhanbad region, catering to a dense population of ~
Slide 5: Journey Over The Years
Journey Over The Years • Started Construction of Cancer • Commenced Operation of Hospital. • Started Operations in the new Cardiac Department. • Installed 20NM3 Oxygen Plant. Cancer Hospital in Ranguni with • Asarfi Hospital • Established Burn • Started Construction of • Land allotted by RSCCL for H
Slide 6: Our Departments and Facilities
Our Departments and Facilities General Paediatrics & Obstetrics & General Cardiology Neurosciences medicine Neonatology Gynaecology Surgery Gastroenterology Orthopaedics Burn & Plastic Oncology Nephrology Urology Surgery Ophthalmology ENT Day Care Dental Physiotherapy Emergency services Sciences Nut
Slide 7: Super-Specialty Hospital and Cancer Hospital
Super-Specialty Hospital Cancer Hospital Year Established: 2005 Year Established: 2024 Location: Situated on the Main Highway, 6 km from Dhanbad Location: Situated in Ranguni, Dhanbad Railway Station Building: 4 Blocks, 6 floors and Constructed area - more than 1 USP: Just 1 out of 3 in the state of
Slide 8: Leadership Team
Leadership Team Harendra Singh Udai Pratap Singh Sukanti Kumar Das Promoter and CFO Promoter and MD Non- Executive Director • A visionary entrepreneur inspired by the • Renowned Consultant Gynaecologist Company’s Purpose—Health for All. • Started his career in 2017, he is a and brings with him over
Slide 9: Financial and Operational Performance
Financial and Operational Performance 8
Slide 10: Key Highlights
Key Highlights Revenue Trend Strong Margins Growing Profitability Key Ratios Consolidated Revenues Q1’FY26 Consolidated EBITDA Margins Consolidated PAT Q1’FY26 FY25 ROCE 14% ₹3,568 lakhs 56% YoY Q1’FY26 – 20% ₹312 lakhs 115% YoY FY25 Debt to Equity 0.6 FY25 Current Ratio 1.4 Standalone Revenues Q1’F
Slide 11: Key Highlights – Strategic Partnership
Key Highlights – Strategic Partnership Signing of MoU Advanced Transplant Capabilities • With a strategic partnership with Gleneagles Hospital Chennai, Asarfi Hospital Dhanbad is • Gleneagles Hospital will provide the specialist set to establish Jharkhand’s first-ever Multi- expertise for this proje
Slide 12: Summary Financial (Standalone)
Summary Financial (Standalone) Revenue from Operations (₹ in Lakhs) EBITDA (₹ in Lakhs) and EBITDA Margin % 800 20% 4,000 21% 3,200 600 15% 2,400 400 1,600 200 2,292 3,389 3,566 800 482 524 703 - - Q1'FY25 Q4'FY25 Q1'FY26 Q1'FY25 Q4'FY25 Q1'FY26 EBIT (₹ in Lakhs) and EBIT Margin % PAT (₹ in Lakhs) a
Slide 13: Summary Financial (Consolidated)
Summary Financial (Consolidated) Revenue from Operations (₹ in Lakhs) EBITDA (₹ in Lakhs) and EBITDA Margin % 800 20% 4,000 21% 3,200 600 15% 2,400 400 1,600 200 2,292 3,389 3,568 800 476 507 699 - - Q1'FY25 Q4'FY25 Q1'FY26 Q1'FY25 Q4'FY25 Q1'FY26 EBIT (₹ in Lakhs) and EBIT Margin % PAT (₹ in Lakhs)
Slide 14: Revenue Mix Q1'FY25 vs Q1'FY26
Revenue Mix Q1’FY25 vs Q1’FY26 Super-Specialty Hospital Unit Cardiology Cardiology General Medicine 12% General Medicine 10% 1% 4% Neurosciences 5% Neurosciences 29% 30% 5% 5% General Surgery General Surgery Department- Department- 9% Paediatrics and 6% wise Revenue Paediatrics and wise Revenue Neon
Slide 15: Revenue Mix Q1'FY25 vs Q1'FY26 – Cancer Hospital
Revenue Mix Q1’FY25 vs Q1’FY26 Cancer Hospital Unit 7% 12% Medical Oncology Medical Oncology 21% 17% Department- Surgical Oncology Department- Surgical Oncology wise Revenue wise Revenue Mix Q1’FY25 54% Radiation Oncology Mix Q1’FY26 Radiation Oncology 8% 65% Others* 17% Others* - In Q1’FY26, the ca
Slide 16: IPD-OPD Data (Both Hospital Units)
IPD-OPD Data (Both Hospital Units) Volumes Revenues (₹ in Lakhs) 35,000 32,986 3,500 30,690 2,997 30,000 3,000 23,825 2,440 25,000 2,500 20,000 2,000 1,848 15,000 1,500 10,000 1,000 927 522 5,000 3,947 500 393 2,516 3,174 0 0 Q1'FY25 Q4'FY25 Q1'FY26 Q1'FY25 Q4'FY25 Q1'FY26 Inpatient Volume Outpatien
Slide 17: ARPOB, Bed Capacity and Occupancy %
ARPOB, Bed Capacity and Occupancy % ARPOB (in ₹) Bed Capacity and Occupancy % Super-Specialty Hospital Unit 25,000 64% 21,052 300 62% 19,398 57% 20,000 250 16,003 15,000 200 10,000 150 100 5,000 50 250 250 250 0 0 Q1'FY25 Q4'FY25 Q1'FY26 Q1'FY25 Q4'FY25 Q1'FY26 ARPOB (in ₹) Bed Capacity and Occupanc
Slide 18: Surgery Count
Surgery Count Surgery Count 1800 1600 54 26 52 82 1400 43 56 53 68 85 88 1200 120 158 161 1000 43 154 48 30 40 800 76 102 498 415 600 122 136 400 462 474 200 413 0 Q1'FY25 Q4'FY25 Q1'FY26 Cardiac Gastro Gen. Surgery Obs & Gyn Orthopedic Neurology Burn & Plastic Surgery ENT Urology 17
Slide 19: Profit and Loss Account (Standalone)
Profit and Loss Account (Standalone) (₹ in Lakhs) Particulars Q1'FY25 Q4'FY25 Q1'FY26 QoQ % YoY% Revenue from operations 2,292 3,389 3,566 5% 56% Material costs (584) (750) (857) 14% 47% Employee benefit expenses (390) (590) (578) -2% 48% Other expenses (836) (1,525) (1,428) -6% 71% EBITDA 482 524 7
Slide 20: Profit and Loss Account (Consolidated)
Profit and Loss Account (Consolidated) (₹ in Lakhs) Particulars Q1'FY25 Q4'FY25 Q1'FY26 QoQ % YoY% Revenue from operations 2,292 3,389 3,568 5% 56% Material costs (584) (750) (857) 14% 47% Employee benefit expenses (390) (592) (580) -2% 49% Other expenses (842) (1,541) (1,431) -7% 70% EBITDA 476 507
Slide 21: Disclosure and Contact Details
Disclosure and Contact Details Certain matters discussed in this presentation may contain statements regarding the company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements do not guarantee future performanc